Mesenchymal stem cells are sensitive to treatment with kinase inhibitors and ionizing radiation;Mesenchymale Stammzellen sind sensitiv gegenüber der Behandlung mit Kinaseinhibitoren und ionisierenden Stahlen

Strahlentherapie und Onkologie

Volumn 190, Issue 11, 2014, Pages 1037-1045

  Nicolay, Nils H ^a,b   Sommer, Eva ^b   Perez, Ramon Lopez ^b   Wirkner, Ute ^b   Bostel, Tilman ^a   Ho, Anthony D ^a   Lahn, Michael ^c   Debus, Jürgen ^a,b   Saffrich, Rainer ^a   Huber, Peter E ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Imatinib; Platelet derived growth factor; Radiotherapy; Receptor tyrosine kinase; Sunitinib

Indexed keywords

PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MESENCHYMAL STROMA CELL; PHYSIOLOGY; RADIATION DOSE; RADIATION RESPONSE;

APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MESENCHYMAL STROMAL CELLS; PROTEIN KINASE INHIBITORS; RADIATION DOSAGE; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;

EID: 84922330010     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0686-1     Document Type: Article

References (43)

1. Kalinina NI, Sysoeva VY, Rubina KA, Parfenova YV, Tkachuk VA (2011) Mesenchymal stem cells in tissue growth and repair. Acta Naturae 3:30–37
2. Hong HS, Kim YH, Son Y (2012) Perspectives on mesenchymal stem cells: tissue repair, immune modulation, and tumor homing. Arch Pharm Res 35:201–211
3. Hayes M, Curley G, Ansari B, Laffey JG (2012) Clinical review: Stem cell therapies for acute lung injury/acute respiratory distress syndrome—hope or hype? Crit Care 16:205
4. Qi Y, Feng G, Yan W (2012) Mesenchymal stem cell-based treatment for cartilage defects in osteoarthritis. Mol Biol Rep 39:5683–5689
5. Williams AR, Hare JM (2011) Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 109:923–940
6. Schmidt M, Haagen J, Noack R, Siegemund A, Gabriel P, Dörr W (2014) Effects of bone marrow or mesenchymal stem cell transplantation on oral mucositis (mouse) induced by fractionated irradiation. Strahlenther Onkol 190:399–404
7. Dörr W, Herrmann T, Baumann M (2014) Application of organ tolerance dose-constraints in clinical studies in radiation oncology. Strahlenther Onkol 190:399–404
8. Goetze K, Meyer SS, Yaromina A, Zips D, Baumann M, Mueller-Klieser W (2013) Glycolysis-related gene induction and ATP reduction during fractionated irradiation. Markers for radiation responsiveness of human tumor xenografts. Strahlenther Onkol 189:782–788
9. Schaue D, Kachikwu EL, McBride WH (2012) Cytokines in radiobiological responses: a review. Radiat Res 178:505–523
10. Milas L, Raju U, Liao Z, Ajani J (2005) Targeting molecular determinants of tumor chemo-radioresistance. Semin Oncol 32:78–81
11. Strasser H, Grabenbauer GG, Sprung CN, Sauer R, Distel LV (2007) DNA double-strand break induction and repair in irradiated lymphoblastoid, fibroblast cell lines and white blood cells from ATM, NBS and radiosensitive patients. Strahlenther Onkol 183:447–453
12. Herskind C, Bamberg M, Rodemann HP (1998) The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 174:12–15
13. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28
14. Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pinter T, Cheng Y et al (2012) Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). J Clin Oncol 30:3596–3603
15. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Grone HJ, Debus J, Lipson KE, Abdollahi A (2005) Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65:3643–3655
16. Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE (2008) Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 14:2210–2219
17. Zhang M, Kleber S, Rohrich M, Timke C, Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U et al (2011) Blockade of TGF-beta signaling by the TGFbetaR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 71:7155–7167
18. Flechsig P, Dadrich M, Bickelhaupt S, Jenne J, Hauser K, Timke C, Peschke P, Hahn EW, Grone HJ, Yingling J et al (2012) LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 18:3616–3627
19. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G et al (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365:1079–1087
20. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201:925–935
21. Wynn TA, Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028–1040
22. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W et al (2005) Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 33:1402–1416
23. Nicolay NH, Sommer E, Lopez R, Wirkner U, Trinh T, Sisombath S, Debus J, Ho AD, Saffrich R, Huber PE (2013) Mesenchymal stem cells retain their defining stem cell characteristics after exposure to ionizing radiation. Int J Radiat Oncol Biol Phys 87:1171–1178
24. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1:2315–2319
25. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, Abbruzzese JL, Chiao PJ (2008) LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 7:829–840
26. Fransvea E, Angelotti U, Antonaci S, Giannelli G (2008) Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47:1557–1566
27. Buchdunger E, O’Reilly T, Wood J (2002) Pharmacology of imatinib (STI571). Eur J Cancer 38:528–536.
28. Backman U, Christofferson R (2005) The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Pediatr Res 57:690–695
29. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652
30. Cain JA, Grisolano JL, Laird AD, Tomasson MH (2004) Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657. Blood 104:561–564
31. Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC et al (2011) TGFbeta1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res 17:6754–6765
32. Borriello A, Caldarelli I, Basile MA, Bencivenga D, Tramontano A, Perrotta S, Della Ragione F, Oliva A (2011) The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PloS one 6:e28555
33. Jonsson S, Hjorth-Hansen H, Olsson B, Wadenvik H, Sundan A, Standal T (2012) Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro. J Bone Miner Metab 30:119–123
34. Plattner R, Koleske AJ, Kazlauskas A, Pendergast AM (2004) Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol 24:2573–2583
35. Ball SG, Shuttleworth CA, Kielty CM (2007) Platelet-derived growth factor receptor-alpha is a key determinant of smooth muscle alpha-actin filaments in bone marrow-derived mesenchymal stem cells. Int J Biochem Cell Biol 39:379–391
36. Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS et al (2008) PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 112:295–307
37. Sweeny L, Zimmermann TM, Liu Z, Rosenthal EL (2012) Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts. Oral Oncol 48:1242–1249
38. Donovan J, Shiwen X, Norman J, Abraham D (2013) Platelet-derived growth factor alpha and beta receptors have overlapping functional activities towards fibroblasts. Fibrogenesis Tissue Repair 6:10
39. Holdhoff M, Kreuzer KA, Appelt C, Scholz R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, Van Etten RA et al (2005) Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 34:181–185
40. Qiao B, Kerr M, Groselj B, Teo MT, Knowles MA, Bristow RG, Phillips RM, Kiltie AE (2013) Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res 73:1611–1620
41. Hardee ME, Marciscano AE, Medina-Ramirez CM, Zagzag D, Narayana A, Lonning SM, Barcellos-Hoff MH (2012) Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res 72:4119–4129
42. Xue J, Li X, Lu Y, Gan L, Zhou L, Wang Y, Lan J, Liu S, Sun L, Jia L et al (2013) Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. Mol Ther 21:456–465
43. Magne N, Chargari C, MacDermed D, Conforti R, Vedrine L, Spano JP, Khayat D (2010) Tomorrow’s targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity? Crit Rev Oncol Hematol 76:186–195